SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome
Liguo ZhangiD, Alexsia L. Richards, Andrew S. KhaliliD, Emile Wogram, Haiting Ma, Richard A. YoungiD, Rudolf JaenischiD
Abstract
Prolonged SARS-CoV-2 RNA shedding and recurrence of PCR-positive tests have been widely reported in patients after recovery, yet these patients most commonly are non-infectious1-14. Here we investigated the possibility that SARS-CoV-2 RNAs can be reverse-transcribed and integrated into the human genome and that transcription of the integrated sequences might account for PCR-positive tests. In support of this hypothesis, we found chimeric transcripts consisting of viral fused to cellular sequences in published data sets of SARS-CoV-2 infected cultured cells and primary cells of patients, consistent with the transcription of viral sequences integrated into the genome. To experimentally corroborate the possibility of viral retro-integration, we describe evidence that SARS-CoV-2 RNAs can be reverse transcribed in human cells by reverse transcriptase (RT) from LINE-1 elements or by HIV-1 RT, and that these DNA sequences can be integrated into the cell genome and subsequently be transcribed. Human endogenous LINE-1 expression was induced upon SARS-CoV-2 infection or by cytokine exposure in cultured cells, suggesting a molecular mechanism for SARS-CoV-2 retro-integration in patients. This novel feature of SARS-CoV-2 infection may explain why patients can continue to produce viral RNA after recovery and suggests a new aspect of RNA virus replication.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 70
- Organism
- Assay
- Research Focus
- Approach
Abstract summary
Claude Opus 5.5 · xhigh effort · 2 Nov 2026 · from the abstract
SARS-CoV-2 RNA can be reverse-transcribed by LINE-1 or HIV-1 reverse transcriptase, integrated into the human genome, and transcribed as chimeric viral-cellular RNAs.
Recovered SARS-CoV-2 patients frequently exhibit prolonged viral RNA shedding and recurrent polymerase chain reaction (PCR)-positive results despite being non-infectious. Investigating published patient and cultured cell datasets alongside experimental assays indicates that reverse transcription and genomic integration of SARS-CoV-2 sequences may explain persistent viral RNA production after recovery.
Key results
ClaimedPublished datasets from SARS-CoV-2-infected cultured cells and primary patient cells contain chimeric transcripts fusing viral and cellular sequences, consistent with transcription of genomically integrated viral sequences.
Detected viral-cellular chimeric transcripts in published datasets of infected cultured cells and patient primary cells; dataset counts and chimeric transcript frequencies are not stated in the abstract. · Abstract
ClaimedSARS-CoV-2 RNA can be reverse-transcribed in human cells by LINE-1 or HIV-1 reverse transcriptase (RT), integrated into the host genome, and subsequently transcribed.
Experimental assays in human cells with LINE-1 RT or HIV-1 RT; specific cell lines and quantitative integration rates are not reported in the abstract. · Abstract
ClaimedSARS-CoV-2 infection or cytokine exposure induces endogenous human LINE-1 expression in cultured cells, providing a candidate mechanism for viral retro-integration.
Measured endogenous LINE-1 expression in cultured cells following SARS-CoV-2 infection or cytokine treatment; fold-change values are not provided in the abstract. · Abstract
Methods, data and reproducibility
The authors searched published datasets from SARS-CoV-2-infected cultured cells and patient primary cells for chimeric viral-cellular transcripts. They then experimentally tested reverse transcription, genomic integration, and subsequent transcription of SARS-CoV-2 RNA in human cells via LINE-1 or HIV-1 reverse transcriptase, and measured endogenous LINE-1 induction after viral infection or cytokine exposure.
- Published datasets of SARS-CoV-2-infected cultured cells and primary cells from patients · human, SARS-CoV-2
- Cultured human cells experimentally tested for LINE-1/HIV-1 reverse transcription, genomic integration, and cytokine/infection-induced LINE-1 expression · human, SARS-CoV-2
- Reproducibility gaps
- Published datasets are referenced without accessions or URLs in the abstract.
Limitations (2)
- Experimental validation of reverse transcription, genomic integration, and LINE-1 induction was performed in cultured cells rather than directly demonstrating integration in patients in vivo. · noted in this summary
- Abstract only; quantitative chimeric transcript counts, integration frequencies, cell types, and dataset accessions are not reported. · noted in this summary
Who should read:Read this if you study SARS-CoV-2 host-virus interactions, endogenous retroelements such as LINE-1, or mechanisms underlying prolonged viral RNA detection after recovery.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2-host chimeric RNA-sequencing reads do not necessarily signify virus integration into the host DNA
A. Kazachenka, G. Kassiotis·bioRxiv·Mar 5, 2021
- LINE1-mediated reverse transcription and genomic integration of SARS-CoV-2 mRNA detected in virus-infected but not in viral mRNA-transfected cells
Liguo Zhang, Punam Bisht, … Rudolf Jaenisch·VirusesPeer-reviewed·Feb 25, 2023
- Comprehensive analysis of RNA-seq and whole genome sequencing data reveals no evidence for SARS-CoV-2 integrating into host genome
Yusheng Chen, Shuaiyao Lu, … Yun‐Gui Yang·Protein & CellPeer-reviewed·Aug 2, 2021
- No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing
Nathan Smits, Jay Rasmussen, … Geoffrey J. Faulkner·Cell ReportsPeer-reviewed·Jul 28, 2021
- Host-virus chimeric events in SARS-CoV2 infected cells are infrequent and artifactual
B. Yan, S. Chakravorty, … M. Kazemian·Journal of VirologyPeer-reviewed·Jul 12, 2021
- Putative host-derived insertions in the genome of circulating SARS-CoV-2 variants
Yi‐Yan Yang, Keith Dufault‐Thompson, … Xiaofang Jiang·mSystemsPeer-reviewed·May 18, 2022